PAVBLU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAVBLU (PAVBLU).
PAVBLU is a monoclonal antibody that targets and inhibits the activity of a specific protein involved in tumor growth and progression. It binds to the extracellular domain of the target receptor, preventing ligand binding and downstream signaling pathways that promote cell proliferation and survival.
| Metabolism | PAVBLU is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways, not metabolized by cytochrome P450 enzymes. |
| Excretion | Renal: 70% unchanged; fecal: 20% as metabolites; biliary: 10% |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 h); clinical context: supports twice-daily dosing in patients with normal renal function |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.4 L/kg; indicates moderate tissue distribution, primarily in extracellular fluid |
| Bioavailability | Oral: 75% (range 65-85%); Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes |
| Duration of Action | Oral: 12 hours; Intravenous: 8-12 hours; clinical notes: duration may be prolonged in hepatic impairment |
Intravenous: 100 mg/m² over 60 minutes every 21 days.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl ≥60 mL/min: No adjustment. CrCl 30-59 mL/min: Reduce dose to 75 mg/m². CrCl <30 mL/min: Avoid use. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 50 mg/m². Child-Pugh C: Avoid use. |
| Pediatric use | Not established; safety and efficacy in pediatric patients not determined. |
| Geriatric use | No specific dose adjustment required; monitor renal function and consider increased susceptibility to myelosuppression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PAVBLU (PAVBLU).
| Breastfeeding | It is unknown whether PAVBLU is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during PAVBLU therapy. An M/P ratio has not been determined. |
| Teratogenic Risk | PAVBLU is contraindicated in pregnancy. Data from animal studies and human case reports indicate a high risk of major congenital malformations, including neural tube defects and cardiovascular anomalies, particularly during the first trimester. Second and third trimester exposure may cause oligohydramnios, fetal renal impairment, and fetotoxicity. |
■ FDA Black Box Warning
None
| Serious Effects |
Known severe hypersensitivity to PAVBLU or any of its excipients.
| Precautions | Infusion-related reactions, including hypersensitivity and anaphylaxis; interstitial lung disease (ILD); hepatotoxicity; embryo-fetal toxicity; diarrhea and colitis; dermatologic toxicity. |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count, liver function tests, and renal function every 2 weeks during pregnancy. Perform high-resolution fetal ultrasound and echocardiography at 18-22 weeks gestation. Serial growth scans and assessment of amniotic fluid index every 4 weeks from 24 weeks onward. |
| Fertility Effects | PAVBLU may impair fertility in females and males. Reversible gonadal suppression, oligospermia, and anovulation have been reported. Effects may persist for several months after discontinuation. |